To assess the long-term efficacy of oral Ziprasidone in the maintenance treatment of
resistant schizophrenic subjects who have benefited from participation in the phase III
ziprasidone study A1281039 (MOZART study), to assess the efficacy of ziprasidone in the
relapse prevention of schizophrenia, to collect long-term data on safety and tolerability of
oral Ziprasidone
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.